Lineage Cell Therapeutics (LCTX) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lineage Cell Therapeutics (LCTX) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 40.5% versus a loss of 60.0%. Lexeo Therapeutics is the larger company by market cap ($263.5 million vs $260.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | LXEO |
|---|---|---|
| Share price | $1.03 | $3.21 |
| Market cap | $260.49M | $263.50M |
| 1-day change | +8.70% | -3.02% |
| YTD return | -38.32% | -67.67% |
| 1-year return | -40.46% | -60.02% |
| 5-year return | -56.17% | — |
| EPS (TTM) | $-0.17 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $10.99 |
| 52-week low | $0.88 | $2.98 |
| Distance from 52-week high | -50.72% | -70.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +433.98% | +532.40% |
| Average volume | 1.15M | 1.20M |
| Shares outstanding | 252.91M | 82.09M |
| Employees | 72 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LCTX has outperformed LXEO by 19.6 percentage points over the past year.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
LCTX vs LXEO FAQ
Which is bigger, Lineage Cell Therapeutics or Lexeo Therapeutics?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $263.50M compared with $260.49M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, LCTX or LXEO?
LCTX returned -40.46% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.